DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud


Yale School of Medicine
New Haven, Estados UnidosPublications in collaboration with researchers from Yale School of Medicine (9)
2022
-
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192
-
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
European Journal of Cancer, Vol. 160, pp. 61-71
-
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
Journal for immunotherapy of cancer, Vol. 10, Núm. 8
2021
-
Enfortumab vedotin in previously treated advanced urothelial carcinoma
New England Journal of Medicine, Vol. 384, Núm. 12, pp. 1125-1135
2020
-
Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
Bladder Cancer, Vol. 6, Núm. 1, pp. 43-52
-
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
The Lancet Oncology, Vol. 21, Núm. 1, pp. 105-120
2017
-
Borealis-1: A randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer
Annals of Oncology, Vol. 28, Núm. 10, pp. 2481-2488
-
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
The Lancet, Vol. 390, Núm. 10109, pp. 2266-2277
-
Strategies to design clinical studies to identify predictive biomarkers in cancer research
Cancer Treatment Reviews, Vol. 53, pp. 79-97